OncoDaily Pulse

Aug 20, 2025, 12:34

Ilya Tsimafeyeu: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register here: https://forms.gle/qcQyaGMQfHDhanfD9

Co-Chair of VIRO

Images

Name

Rana McKay

Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Ilya Tsimafeyeu

Dr. Ilya Tsimafeyeu is a leading oncologist from Russia and the Founder and Chairman of the Russian Society of Oncologists (RUSSCO). He is internationally recognized for his contributions to genitourinary cancers, particularly renal cell carcinoma (RCC), and has played a pivotal role in expanding access to innovative cancer therapies in Russia and Eastern Europe.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Tsimafeyeu will present on “Real-World Evaluation of Treatment Approaches and Immunotherapy Outcomes in Russia”. His talk focuses on how real-world data (RWD) can complement clinical trial findings, offering a clearer picture of how therapies perform in routine practice outside of controlled trial settings.

Dr. Tsimafeyeu will share insights into

Patterns of treatment use in the Russian oncology landscape.
Efficacy and safety outcomes of immunotherapy in real-world patient populations.
The importance of local and regional data to guide evidence-based decisions where global trial populations may not fully reflect local practice.

By evaluating real-world immunotherapy outcomes, Dr. Tsimafeyeu emphasizes the value of tailoring treatment approaches to regional healthcare systems, ensuring that innovations translate effectively into practice. His work demonstrates the growing importance of global collaboration and local data integration in advancing equitable cancer care worldwide.